查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1806194

感染疾病诊断市场按产品类型、样本类型、检测类型、病原体类型、疾病类型和最终用户划分 - 全球预测 2025-2030

Infectious Disease Diagnostic Market by Product, Sample Type, Testing Type, Pathogen Type, Disease Type, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2024年感染疾病诊断市值将达240.7亿美元，2025年成长至261.3亿美元，复合年增长率为8.82%，到2030年将达到400亿美元。

主要市场统计数据
基准年2024年 240.7亿美元
预计2025年 261.3亿美元
预测年份 2030 400亿美元
复合年增长率（%） 8.82%

揭示影响现代感染疾病检测的关键驱动因素和创新

感染疾病诊断领域正处于关键的十字路口，临床对更快、更准确结果的需求日益增长，而仪器和软体整合的技术突破也不断涌现。实验室和即时诊断 (POC)整体面临快速病原体检测的压力，同时也要维持严格的敏感度和特异性标准。在此背景下，从医院网路到学术研究机构，医疗保健领域的相关人员必须调整其营运模式，以充分利用下一代工具和工作流程。

自动化、数据分析和分散式检查模型如何彻底改变病原体检测和临床决策途径

自动化、高通量能力和数据分析的结合正在重塑感染疾病诊断领域，使实验室能够以前所未有的规模处理检体。与质谱和次世代定序相容的尖端检测方法与免疫测量和PCR技术相辅相成，能够以极快的周转时间对细菌、病毒、真菌和寄生虫病原体进行多重检测。

克服新的贸易壁垒和策略采购调整，以在不断变化的关税制度下维持诊断测试业务

2025年全年实施的关税政策增加了用于传染病检查的进口试剂、设备和关键零件的成本。许多诊断实验室从疫区购买的抗原检测套件和免疫检测分析仪的成本上涨，迫使采购团队寻找其他国内供应商或调整检测量以缓解预算限制。

整合产品、检体、测试、病原体、疾病和最终用户的观点，定义客製化的诊断途径

有效的细分方法可以揭示产品类型之间的微妙驱动因素，并揭示仪器、套件和试剂盒以及软体解决方案的清晰采用模式。在仪器中，免疫检测分析仪满足了常规筛检的临床需求，而质谱仪和微阵列则满足了专门的研究应用。 PCR 系统在中心实验室和照护现场中都越来越受欢迎。试剂和套件用途广泛：抗原检测在快速检测场景中表现出色，ELISA 和免疫测量套件支持高通量工作流程，而 PCR套件则为分子诊断提供了无与伦比的灵敏度。

检验区域医疗保健基础设施和影响全球诊断创新和采用模式的政策驱动因素

在美洲地区，成熟的医疗基础设施和强大的报销框架持续支持先进诊断平台的采用。在北美，由参考实验室和学术研究中心组成的网路正在引领新型检测方法的检验；而在拉丁美洲，不断扩展的公共卫生计画正在推动对经济高效、快速检测方法的需求。经济多元化和政府对分子诊断技术的投入正在增强大规模筛检计画的能力。

探索策略合作伙伴关係和平台整合，以推动更快的检测开发和可扩展的诊断解决方案

聚焦推动诊断卓越发展的关键创新者和策略伙伴关係

一群知名仪器製造商和新兴试剂开发人员正在携手合作，加速将研究级检测转化为临床应用。微阵列供应商与软体公司之间的合作实现了无缝的数据解读流程，而套件製造商与参考实验室之间的合作则确保了在各种临床条件下进行严格的性能检验。

建立弹性製造、数据主导洞察和协力网路，以加速诊断敏捷性和市场回应

高阶主管应优先考虑实现製造地多元化，以缓解供应链脆弱性，并降低贸易政策波动带来的风险。采用关键试剂和设备的弹性生产模式，使企业能够根据当地疫情情况快速扩大产量。此外，投资模组化、软体主导的平台，有助于无缝整合新的检测化学方法，从而加快新兴病原体靶点的上市时间。

严格的资料收集、专家访谈和详细的分类框架确保客观且可操作的市场分析

我们的分析整合了对诊断实验室、套件製造商、软体开发商和医疗政策制定者高管进行深入访谈所获得的主要见解。二次研究则利用同侪审查期刊、监理备案文件和公共卫生机构报告，以检验科技采用趋势和区域部署模式。我们应用了专有框架来绘製产品和疾病分类，以确保仪器、试剂、样本类型和最终用户细分的一致性。

自适应技术和协作策略在塑造未来感染疾病检测中的作用日益增强

随着全球医疗生态系统持续面临新兴感染疾病的威胁，快速检测和鑑定病原体的能力仍然是有效应对策略的核心。检测方法的技术进步，加上强大的软体整合和分散式检查能力，正在重新定义诊断工作流程，并实现主动的患者管理。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概述

第五章市场动态

  • 对快速诊断以便早期发现感染疾病的需求日益增加
  • 实施人工智慧预测分析，优化疫情监测与因应策略
  • 机场和公共设施对快速抗原检测的需求增加将改善社区安全
  • 扩大照护现场多重检测，提高分散式传染病检查的可及性
  • 基于 CRISPR 的诊断技术的整合简化了快速病原体检测工作流程。
  • 拓展远端医疗协作诊疗平台，加速远距感染疾病管理
  • 次世代定序的进步使得临床实验室能够全面鑑定病原体
  • 转向家用分子检测套组，以病人为中心的感染疾病监测
  • 基因组工具助力感染追踪新时代
  • 利用数位生物标记和穿戴式感测器在症状出现之前预测感染的发生

第六章 市场洞察

  • 波特五力分析
  • PESTEL分析

第七章 2025年美国关税的累积影响

第八章感染疾病诊断市场（按产品）

  • 装置
    • 免疫检测分析仪
    • 质谱仪
    • 微阵列
    • PCR体系
  • 试剂和套件
    • 抗原检测试剂套件
    • ELISA套件
    • 免疫检测套件
    • PCR套件
  • 软体

第九章感染疾病诊断市场（依样本类型）

  • 血
    • 电浆
    • 血清
    • 全血
  • 航班
  • 拭子
    • 鼻腔
    • 直肠
    • 喉
  • 尿

第 10 章感染疾病诊断市场（依测试类型）

  • 实验室检查
  • PoC 测试

第11章感染疾病诊断市场（依病原体类型）

  • 细菌
  • 真菌
  • 寄生虫
  • 病毒
    • 肝炎
    • HIV
    • 流感

第十二章感染疾病诊断市场（依疾病类型）

  • 细菌感染疾病
    • 脑膜炎
    • 肺炎
    • 结核
  • 霉菌感染疾病
    • 曲菌症
    • 念珠菌症
    • 隐球菌病
  • 寄生虫感染疾病
    • 利什曼原虫症
    • 疟疾
    • 血吸虫病
  • 媒介性行为感染感染
    • 登革热
    • 莱姆病
    • 兹卡病毒
  • 病毒感染疾病
    • 肝炎（甲型、乙型、丙型）
    • 爱滋病毒/爱滋病
    • 流感

第十三章感染疾病诊断市场（依最终用户）

  • 学术研究机构
  • 诊断实验室
  • 医院和诊所

14.美洲感染疾病诊断市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 阿根廷

15. 欧洲、中东和非洲感染疾病诊断市场

  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 阿拉伯聯合大公国
  • 沙乌地阿拉伯
  • 南非
  • 丹麦
  • 荷兰
  • 卡达
  • 芬兰
  • 瑞典
  • 奈及利亚
  • 埃及
  • 土耳其
  • 以色列
  • 挪威
  • 波兰
  • 瑞士

16.亚太感染疾病诊断市场

  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国
  • 印尼
  • 泰国
  • 菲律宾
  • 马来西亚
  • 新加坡
  • 越南
  • 台湾

第十七章竞争格局

  • 2024年市场占有率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Bio-Rad Laboratories, Inc.
    • F. Hoffmann-La Roche Ltd.
    • Abbott Laboratories
    • Adaptive Biotechnologies Corporation
    • Agilent Technologies, Inc.
    • Becton, Dickinson and Company
    • Bio-Techne Corporation
    • bioMerieux SA
    • Boston Scientific Corporation
    • Bruker Corporation
    • Cardinal Health Inc.
    • Cook Medical Incorporated
    • Danaher Corporation
    • GE HealthCare Technologies Inc.
    • Grifols, SA
    • Hologic Inc.
    • Illumina, Inc.
    • Johnson & Johnson Services Inc.
    • Konica Minolta, Inc.
    • Koninklijke Philips NV
    • MedMira Inc.
    • Medtronic PLC
    • Merck KGaA
    • Olympus Corporation
    • Perkin Elmer, Inc.
    • Pfizer Inc.
    • Qiagen NV
    • Quest Diagnostics Incorporated
    • Siemens Healthineers AG
    • Sysmex Corporation
    • Thermo Fisher Scientific, Inc.
    • Trivitron Healthcare

第十八章 研究人工智慧

第十九章 研究统计

第二十章 研究联络人

第21章 研究报导

第22章 附录

Product Code: MRR-4316E4E89510

The Infectious Disease Diagnostic Market was valued at USD 24.07 billion in 2024 and is projected to grow to USD 26.13 billion in 2025, with a CAGR of 8.82%, reaching USD 40.00 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 24.07 billion
Estimated Year [2025] USD 26.13 billion
Forecast Year [2030] USD 40.00 billion
CAGR (%) 8.82%

Unveiling Critical Drivers and Technological Innovations Shaping Modern Infectious Disease Detection

The infectious disease diagnostics arena stands at a pivotal juncture, where technological breakthroughs in instrumentation and software integration converge with rising clinical demands for faster, more precise results. Laboratories and point-of-care settings alike are under increasing pressure to deliver rapid pathogen detection while maintaining rigorous standards of sensitivity and specificity. In this context, stakeholders across the healthcare spectrum-ranging from hospital networks to academic research institutes-must adapt their operational frameworks to harness next-generation tools and workflows.

Against this backdrop, this executive summary synthesizes critical drivers shaping the diagnostics market, highlights regulatory and policy trends influencing global supply chains, and presents actionable frameworks for segmentation, regional analysis, and competitive positioning. By exploring transformative shifts, tariff impacts, and nuanced market segmentation, readers will gain a holistic perspective on how to navigate the complexities of diagnostic innovation, optimize resource allocation, and deliver improved patient outcomes in an increasingly interconnected healthcare ecosystem.

How Automation, Data Analytics, and Decentralized Testing Models Are Revolutionizing Pathogen Detection and Clinical Decision Pathways

The infectious disease diagnostic sector is being reshaped by a convergence of automation, high-throughput capabilities, and data analytics that enable laboratories to process samples at unprecedented scale. Cutting-edge assays compatible with mass spectrometry and next-generation sequencing are complementing immunoassay and PCR technologies, allowing for multiplexed detection of bacterial, viral, fungal, and parasitic pathogens with remarkable turnaround times.

Meanwhile, the integration of cloud-enabled software platforms has streamlined data aggregation from instruments such as immunoassay analyzers and microarrays, supporting real-time surveillance and predictive modeling of outbreak patterns. This shift toward decentralized testing is further bolstered by advanced portable PCR systems and antigen detection kits, extending diagnostic reach beyond centralized labs into point-of-care settings. Consequently, clinical decision-making pathways are evolving to incorporate telehealth consultations informed by rapid test results, signaling a fundamental transformation in how infectious diseases are identified, monitored, and managed on a global scale.

Navigating New Trade Barriers and Strategic Sourcing Adjustments to Sustain Diagnostic Testing Operations Under Evolving Tariff Regimes

Tariff policies implemented throughout 2025 have introduced new cost considerations for imported reagents, instruments, and key components used in infectious disease testing. Many diagnostic laboratories have encountered increased expenses for antigen detection kits and immunoassay analyzers sourced from affected regions, prompting procurement teams to explore alternative domestic suppliers or adjust testing volumes to mitigate budgetary constraints.

In parallel, reagent and kit manufacturers have responded by diversifying regional manufacturing footprints, establishing production lines for ELISA, immunoassay, and PCR kits in tariff-exempt jurisdictions. Software developers for laboratory information management systems have also recalibrated pricing models to accommodate higher import costs for hardware integrations. Collectively, these measures have fostered a more resilient supply chain, though stakeholders must remain vigilant to potential delays and regulatory changes that could further influence global trade dynamics.

Integrating Product, Sample, Testing, Pathogen, Disease, and End-User Perspectives to Illuminate Tailored Diagnostic Pathways

An effective segmentation approach illuminates the nuanced drivers across product categories, revealing distinct adoption patterns in instruments, reagents and kits, and software solutions. Within instruments, immunoassay analyzers maintain strong clinical demand for routine screenings, while mass spectrometers and microarrays cater to specialized research applications. PCR systems continue to expand their footprint in both centralized laboratories and point-of-care settings. Reagents and kits exhibit diverse usage; antigen detection formats excel in rapid testing scenarios, ELISA and immunoassay kits underpin high-throughput workflows, and PCR kits deliver unmatched sensitivity for molecular diagnostics.

Sample type differentiation underscores the importance of specimen matrix compatibility, with blood derivatives such as plasma, serum, and whole blood dominating hospital-based testing and stool and urine assays facilitating gastrointestinal and urinary pathogen detection. Swab collections, spanning nasal, rectal, and throat formats, are pivotal for respiratory screening programs. Diagnostic methodologies fall broadly into laboratory testing and point-of-care modalities, each aligned with specific clinical contexts and throughput requirements. Pathogen focus spans bacterial, fungal, parasitic, and viral targets; within the viral cohort, hepatitis subtypes, HIV, and influenza command critical surveillance priority. Disease classifications span meningitis and pneumonia to vector-borne infections such as dengue and Zika, informing tailored assay development. Finally, end-user environments ranging from academic institutes to diagnostic laboratories and hospitals guide commercialization strategies and service level agreements for comprehensive diagnostic platforms.

Examining Regional Healthcare Infrastructures and Policy Drivers That Shape Diagnostic Innovation and Adoption Patterns Globally

In the Americas region, mature healthcare infrastructures and robust reimbursement frameworks continue to drive adoption of advanced diagnostic platforms. North America's network of reference laboratories and academic research centers spearheads validation of novel assays, while Latin American markets exhibit growing demand for cost-effective rapid tests amid expanding public health initiatives. Economic diversification and government investments in molecular diagnostics have bolstered capacity for large-scale screening programs.

Europe, Middle East, and Africa present a mosaic of requirements, from stringent regulatory compliance in Western Europe to emerging surveillance needs in the Middle East and resource-constrained settings across Africa. Collaborative efforts among public health agencies have accelerated deployment of point-of-care antigen tests and portable PCR systems during outbreak responses, redefining standard practices for decentralized testing.

Asia-Pacific markets showcase dynamic growth fueled by rising awareness of infectious disease preparedness and expanding digital health ecosystems. Government initiatives in countries such as China and India are catalyzing local manufacturing capabilities for reagents and instruments, while Southeast Asian nations integrate multiplexed assays into national screening programs. Across all regions, the convergence of technology, policy, and infrastructure investments is shaping a more agile and responsive diagnostic landscape.

Exploring Strategic Alliances and Platform Integrations Driving Faster Assay Development and Scalable Diagnostic Solutions

Spotlight on Leading Innovators and Strategic Collaborations Elevating Diagnostic Excellence

A cohort of established instrument manufacturers and emerging reagent developers are forging collaborative alliances to accelerate the translation of research-grade assays into clinical practice. Partnerships between microarray providers and software firms have enabled seamless data interpretation pipelines, while joint ventures between kit manufacturers and reference laboratories ensure rigorous performance validation under diverse clinical conditions.

Key diagnostic companies are investing in modular instrument architectures that support rapid assay deployment, leveraging scalable reagent supply chains to meet fluctuating demand during epidemic surges. Software integrators are enhancing interoperability with electronic health record systems to deliver actionable insights directly to clinicians. Collectively, these strategic initiatives underscore a shared commitment to driving continuous innovation, optimizing operational efficiencies, and strengthening the global diagnostics ecosystem through synergistic partnerships.

Building Resilient Manufacturing, Data-Driven Insights, and Collaborative Networks to Accelerate Diagnostic Agility and Market Response

Executives should prioritize the diversification of manufacturing footprints to mitigate supply chain vulnerabilities and reduce exposure to trade policy fluctuations. By adopting flexible production models for key reagents and instruments, organizations can rapidly scale output in response to local outbreak scenarios. Moreover, investing in modular, software-driven platforms will facilitate the seamless integration of new assay chemistries, shortening time to market for emerging pathogen targets.

Leaders must also foster cross-sector collaborations that bridge academic research, clinical laboratories, and public health agencies, creating feedback loops for continuous assay refinement. Embracing data-driven decision-making frameworks-leveraging predictive analytics from real-world testing data-will empower stakeholders to anticipate shifts in pathogen prevalence and deploy targeted diagnostic interventions. Finally, building comprehensive education programs for end-users can drive proficiency in advanced testing methodologies, ensuring optimal utilization of instruments and reagents across diverse care settings.

Detailing Rigorous Data Gathering, Expert Interviews, and Taxonomy Frameworks That Ensure Objective and Actionable Market Analysis

Our analysis synthesizes primary insights from in-depth interviews with senior executives at diagnostic laboratories, kit manufacturers, software developers, and healthcare policymakers. Secondary research leveraged peer-reviewed journals, regulatory filings, and public health agency reports to validate technology adoption trends and regional deployment patterns. Proprietary frameworks were applied to map product and disease classifications, ensuring a consistent taxonomy across instruments, reagents, sample types, and end-user segments.

Quantitative data was cross-referenced with historical trade and policy databases to assess tariff impacts, while real-world usage statistics were examined to refine segmentation insights. Scenario planning exercises facilitated the evaluation of strategic sourcing options and partnership models. All findings were peer reviewed by subject matter experts to ensure accuracy, relevance, and practical applicability for decision-makers seeking strategic guidance in the dynamic infectious disease diagnostics market.

Reinforcing the Role of Adaptive Technologies and Collaborative Strategies in Shaping the Future of Infectious Disease Detection

As the global healthcare ecosystem continues to confront emerging infectious threats, the ability to rapidly detect and characterize pathogens remains the cornerstone of effective response strategies. Technological advancements in assay modalities, combined with robust software integration and decentralized testing capabilities, are redefining diagnostic workflows and enabling proactive patient management.

By embracing diversified manufacturing, leveraging real-world data analytics, and cultivating strategic partnerships, stakeholders can navigate regulatory and trade complexities while delivering high-impact diagnostic solutions. Ultimately, the organizations that align operational agility with a deep understanding of regional and segment-specific dynamics will secure leadership positions and contribute meaningfully to improved global health outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Market Sizing & Forecasting

5. Market Dynamics

  • 5.1. Rising need for rapid diagnostics for early detection of infectious diseases
  • 5.2. Adoption of AI-driven predictive analytics optimizing outbreak surveillance and response strategies
  • 5.3. Increasing demand for rapid antigen screening in airports and public venues enhancing community safety
  • 5.4. Expansion of point-of-care multiplex assays driving decentralized infectious disease testing accessibility
  • 5.5. Integration of CRISPR-based diagnostics streamlining rapid pathogen detection workflows
  • 5.6. Expansion of telehealth-linked diagnostic platforms accelerating remote infectious disease management
  • 5.7. Advancements in next-generation sequencing enabling comprehensive pathogen identification in clinical labs
  • 5.8. Shift toward at-home molecular testing kits empowering patient-centric infectious disease monitoring
  • 5.9. Genomic tools powering the new era of infection tracking
  • 5.10. Implementation of digital biomarkers and wearable sensors to predict infection onset before symptoms

6. Market Insights

  • 6.1. Porter's Five Forces Analysis
  • 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Infectious Disease Diagnostic Market, by Product

  • 8.1. Introduction
  • 8.2. Instruments
    • 8.2.1. Immunoassay Analyzers
    • 8.2.2. Mass Spectrometers
    • 8.2.3. Microarrays
    • 8.2.4. PCR Systems
  • 8.3. Reagents & Kits
    • 8.3.1. Antigen Detection Kits
    • 8.3.2. ELISA Kits
    • 8.3.3. Immunoassay Kits
    • 8.3.4. PCR Kits
  • 8.4. Software

9. Infectious Disease Diagnostic Market, by Sample Type

  • 9.1. Introduction
  • 9.2. Blood
    • 9.2.1. Plasma
    • 9.2.2. Serum
    • 9.2.3. Whole Blood
  • 9.3. Stool
  • 9.4. Swab
    • 9.4.1. Nasal
    • 9.4.2. Rectal
    • 9.4.3. Throat
  • 9.5. Urine

10. Infectious Disease Diagnostic Market, by Testing Type

  • 10.1. Introduction
  • 10.2. Laboratory Testing
  • 10.3. PoC Testing

11. Infectious Disease Diagnostic Market, by Pathogen Type

  • 11.1. Introduction
  • 11.2. Bacterial
  • 11.3. Fungal
  • 11.4. Parasitic
  • 11.5. Viral
    • 11.5.1. Hepatitis
    • 11.5.2. HIV
    • 11.5.3. Influenza

12. Infectious Disease Diagnostic Market, by Disease Type

  • 12.1. Introduction
  • 12.2. Bacterial Infectious Diseases
    • 12.2.1. Meningitis
    • 12.2.2. Pneumonia
    • 12.2.3. Tuberculosis
  • 12.3. Fungal Infections
    • 12.3.1. Aspergillosis
    • 12.3.2. Candidiasis
    • 12.3.3. Cryptococcosis
  • 12.4. Parasitic Infections
    • 12.4.1. Leishmaniasis
    • 12.4.2. Malaria
    • 12.4.3. Schistosomiasis
  • 12.5. Vector-borne Infections
    • 12.5.1. Dengue Fever
    • 12.5.2. Lyme Disease
    • 12.5.3. Zika Virus
  • 12.6. Viral Infectious Diseases
    • 12.6.1. Hepatitis (A, B, C)
    • 12.6.3. HIV/AIDS
    • 12.6.4. Influenza

13. Infectious Disease Diagnostic Market, by End-User

  • 13.1. Introduction
  • 13.2. Academic & Research Institutes
  • 13.3. Diagnostic Laboratories
  • 13.4. Hospitals & Clinics

14. Americas Infectious Disease Diagnostic Market

  • 14.1. Introduction
  • 14.2. United States
  • 14.3. Canada
  • 14.4. Mexico
  • 14.5. Brazil
  • 14.6. Argentina

15. Europe, Middle East & Africa Infectious Disease Diagnostic Market

  • 15.1. Introduction
  • 15.2. United Kingdom
  • 15.3. Germany
  • 15.4. France
  • 15.5. Russia
  • 15.6. Italy
  • 15.7. Spain
  • 15.8. United Arab Emirates
  • 15.9. Saudi Arabia
  • 15.10. South Africa
  • 15.11. Denmark
  • 15.12. Netherlands
  • 15.13. Qatar
  • 15.14. Finland
  • 15.15. Sweden
  • 15.16. Nigeria
  • 15.17. Egypt
  • 15.18. Turkey
  • 15.19. Israel
  • 15.20. Norway
  • 15.21. Poland
  • 15.22. Switzerland

16. Asia-Pacific Infectious Disease Diagnostic Market

  • 16.1. Introduction
  • 16.2. China
  • 16.3. India
  • 16.4. Japan
  • 16.5. Australia
  • 16.6. South Korea
  • 16.7. Indonesia
  • 16.8. Thailand
  • 16.9. Philippines
  • 16.10. Malaysia
  • 16.11. Singapore
  • 16.12. Vietnam
  • 16.13. Taiwan

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Bio-Rad Laboratories, Inc.
    • 17.3.2. F. Hoffmann-La Roche Ltd.
    • 17.3.3. Abbott Laboratories
    • 17.3.4. Adaptive Biotechnologies Corporation
    • 17.3.5. Agilent Technologies, Inc.
    • 17.3.6. Becton, Dickinson and Company
    • 17.3.7. Bio-Techne Corporation
    • 17.3.8. bioMerieux SA
    • 17.3.9. Boston Scientific Corporation
    • 17.3.10. Bruker Corporation
    • 17.3.11. Cardinal Health Inc.
    • 17.3.12. Cook Medical Incorporated
    • 17.3.13. Danaher Corporation
    • 17.3.14. GE HealthCare Technologies Inc.
    • 17.3.15. Grifols, S.A.
    • 17.3.16. Hologic Inc.
    • 17.3.17. Illumina, Inc.
    • 17.3.18. Johnson & Johnson Services Inc.
    • 17.3.19. Konica Minolta, Inc.
    • 17.3.20. Koninklijke Philips N.V.
    • 17.3.21. MedMira Inc.
    • 17.3.22. Medtronic PLC
    • 17.3.23. Merck KGaA
    • 17.3.24. Olympus Corporation
    • 17.3.25. Perkin Elmer, Inc.
    • 17.3.26. Pfizer Inc.
    • 17.3.27. Qiagen N.V.
    • 17.3.28. Quest Diagnostics Incorporated
    • 17.3.29. Siemens Healthineers AG
    • 17.3.30. Sysmex Corporation
    • 17.3.31. Thermo Fisher Scientific, Inc.
    • 17.3.32. Trivitron Healthcare

18. ResearchAI

19. ResearchStatistics

20. ResearchContacts

21. ResearchArticles

22. Appendix

LIST OF FIGURES

  • FIGURE 1. INFECTIOUS DISEASE DIAGNOSTIC MARKET RESEARCH PROCESS
  • FIGURE 2. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 3. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 4. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2024 VS 2030 (%)
  • FIGURE 6. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2030 (%)
  • FIGURE 8. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2024 VS 2030 (%)
  • FIGURE 10. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PATHOGEN TYPE, 2024 VS 2030 (%)
  • FIGURE 12. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PATHOGEN TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY DISEASE TYPE, 2024 VS 2030 (%)
  • FIGURE 14. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY DISEASE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 15. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
  • FIGURE 16. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 17. AMERICAS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 18. AMERICAS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 19. UNITED STATES INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 20. UNITED STATES INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 23. ASIA-PACIFIC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 24. ASIA-PACIFIC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 25. INFECTIOUS DISEASE DIAGNOSTIC MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 26. INFECTIOUS DISEASE DIAGNOSTIC MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 27. INFECTIOUS DISEASE DIAGNOSTIC MARKET: RESEARCHAI
  • FIGURE 28. INFECTIOUS DISEASE DIAGNOSTIC MARKET: RESEARCHSTATISTICS
  • FIGURE 29. INFECTIOUS DISEASE DIAGNOSTIC MARKET: RESEARCHCONTACTS
  • FIGURE 30. INFECTIOUS DISEASE DIAGNOSTIC MARKET: RESEARCHARTICLES

LIST OF TABLES

  • TABLE 1. INFECTIOUS DISEASE DIAGNOSTIC MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, 2025-2030 (USD MILLION)
  • TABLE 5. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 7. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 9. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 11. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 13. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY IMMUNOASSAY ANALYZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY IMMUNOASSAY ANALYZERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 15. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY MASS SPECTROMETERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY MASS SPECTROMETERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 17. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY MICROARRAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY MICROARRAYS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 19. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PCR SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PCR SYSTEMS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 21. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
  • TABLE 23. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 25. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY ANTIGEN DETECTION KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY ANTIGEN DETECTION KITS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 27. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY ELISA KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY ELISA KITS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 29. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY IMMUNOASSAY KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY IMMUNOASSAY KITS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 31. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PCR KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PCR KITS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 33. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REAGENTS & KITS, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REAGENTS & KITS, 2025-2030 (USD MILLION)
  • TABLE 35. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SOFTWARE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 37. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
  • TABLE 39. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BLOOD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BLOOD, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 41. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PLASMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PLASMA, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 43. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SERUM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SERUM, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 45. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 47. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BLOOD, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BLOOD, 2025-2030 (USD MILLION)
  • TABLE 49. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY STOOL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY STOOL, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 51. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SWAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SWAB, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 53. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY NASAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY NASAL, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 55. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY RECTAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY RECTAL, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 57. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY THROAT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY THROAT, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 59. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SWAB, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SWAB, 2025-2030 (USD MILLION)
  • TABLE 61. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY URINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY URINE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 63. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2025-2030 (USD MILLION)
  • TABLE 65. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY LABORATORY TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY LABORATORY TESTING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 67. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY POC TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY POC TESTING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 69. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PATHOGEN TYPE, 2025-2030 (USD MILLION)
  • TABLE 71. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BACTERIAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BACTERIAL, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 73. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY FUNGAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY FUNGAL, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 75. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PARASITIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PARASITIC, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 77. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 79. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY HEPATITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY HEPATITIS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 81. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY HIV, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY HIV, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 83. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY INFLUENZA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY INFLUENZA, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 85. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL, 2025-2030 (USD MILLION)
  • TABLE 87. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 89. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BACTERIAL INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BACTERIAL INFECTIOUS DISEASES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 91. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY MENINGITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY MENINGITIS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 93. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PNEUMONIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PNEUMONIA, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 95. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TUBERCULOSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TUBERCULOSIS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 97. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BACTERIAL INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BACTERIAL INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
  • TABLE 99. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY FUNGAL INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY FUNGAL INFECTIONS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 101. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY ASPERGILLOSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY ASPERGILLOSIS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 103. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY CANDIDIASIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY CANDIDIASIS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 105. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY CRYPTOCOCCOSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY CRYPTOCOCCOSIS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 107. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY FUNGAL INFECTIONS, 2025-2030 (USD MILLION)
  • TABLE 109. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PARASITIC INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PARASITIC INFECTIONS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 111. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY LEISHMANIASIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY LEISHMANIASIS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 113. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY MALARIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY MALARIA, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 115. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SCHISTOSOMIASIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SCHISTOSOMIASIS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 117. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PARASITIC INFECTIONS, 2025-2030 (USD MILLION)
  • TABLE 119. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VECTOR-BORNE INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VECTOR-BORNE INFECTIONS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 121. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY DENGUE FEVER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY DENGUE FEVER, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 123. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY LYME DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY LYME DISEASE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 125. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY ZIKA VIRUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY ZIKA VIRUS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 127. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VECTOR-BORNE INFECTIONS, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VECTOR-BORNE INFECTIONS, 2025-2030 (USD MILLION)
  • TABLE 129. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL INFECTIOUS DISEASES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 131. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY HEPATITIS (A, B, C), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY HEPATITIS (A, B, C), BY REGION, 2025-2030 (USD MILLION)
  • TABLE 133. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY HEPATITIS B & C, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY HEPATITIS B & C, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 135. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY HIV/AIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY HIV/AIDS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 137. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY INFLUENZA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY INFLUENZA, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 139. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
  • TABLE 141. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 143. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 145. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 147. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 149. AMERICAS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 150. AMERICAS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 151. AMERICAS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 152. AMERICAS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
  • TABLE 153. AMERICAS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REAGENTS & KITS, 2018-2024 (USD MILLION)
  • TABLE 154. AMERICAS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REAGENTS & KITS, 2025-2030 (USD MILLION)
  • TABLE 155. AMERICAS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 156. AMERICAS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
  • TABLE 157. AMERICAS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BLOOD, 2018-2024 (USD MILLION)
  • TABLE 158. AMERICAS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BLOOD, 2025-2030 (USD MILLION)
  • TABLE 159. AMERICAS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SWAB, 2018-2024 (USD MILLION)
  • TABLE 160. AMERICAS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SWAB, 2025-2030 (USD MILLION)
  • TABLE 161. AMERICAS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2024 (USD MILLION)
  • TABLE 162. AMERICAS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2025-2030 (USD MILLION)
  • TABLE 163. AMERICAS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 164. AMERICAS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PATHOGEN TYPE, 2025-2030 (USD MILLION)
  • TABLE 165. AMERICAS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL, 2018-2024 (USD MILLION)
  • TABLE 166. AMERICAS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL, 2025-2030 (USD MILLION)
  • TABLE 167. AMERICAS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 168. AMERICAS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 169. AMERICAS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BACTERIAL INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 170. AMERICAS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BACTERIAL INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
  • TABLE 171. AMERICAS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2024 (USD MILLION)
  • TABLE 172. AMERICAS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY FUNGAL INFECTIONS, 2025-2030 (USD MILLION)
  • TABLE 173. AMERICAS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2024 (USD MILLION)
  • TABLE 174. AMERICAS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PARASITIC INFECTIONS, 2025-2030 (USD MILLION)
  • TABLE 175. AMERICAS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VECTOR-BORNE INFECTIONS, 2018-2024 (USD MILLION)
  • TABLE 176. AMERICAS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VECTOR-BORNE INFECTIONS, 2025-2030 (USD MILLION)
  • TABLE 177. AMERICAS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 178. AMERICAS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
  • TABLE 179. AMERICAS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 180. AMERICAS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 181. AMERICAS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. AMERICAS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 183. UNITED STATES INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 184. UNITED STATES INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 185. UNITED STATES INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 186. UNITED STATES INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
  • TABLE 187. UNITED STATES INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REAGENTS & KITS, 2018-2024 (USD MILLION)
  • TABLE 188. UNITED STATES INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REAGENTS & KITS, 2025-2030 (USD MILLION)
  • TABLE 189. UNITED STATES INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 190. UNITED STATES INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
  • TABLE 191. UNITED STATES INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BLOOD, 2018-2024 (USD MILLION)
  • TABLE 192. UNITED STATES INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BLOOD, 2025-2030 (USD MILLION)
  • TABLE 193. UNITED STATES INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SWAB, 2018-2024 (USD MILLION)
  • TABLE 194. UNITED STATES INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SWAB, 2025-2030 (USD MILLION)
  • TABLE 195. UNITED STATES INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2024 (USD MILLION)
  • TABLE 196. UNITED STATES INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2025-2030 (USD MILLION)
  • TABLE 197. UNITED STATES INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 198. UNITED STATES INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PATHOGEN TYPE, 2025-2030 (USD MILLION)
  • TABLE 199. UNITED STATES INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL, 2018-2024 (USD MILLION)
  • TABLE 200. UNITED STATES INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL, 2025-2030 (USD MILLION)
  • TABLE 201. UNITED STATES INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 202. UNITED STATES INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 203. UNITED STATES INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BACTERIAL INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 204. UNITED STATES INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BACTERIAL INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
  • TABLE 205. UNITED STATES INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2024 (USD MILLION)
  • TABLE 206. UNITED STATES INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY FUNGAL INFECTIONS, 2025-2030 (USD MILLION)
  • TABLE 207. UNITED STATES INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2024 (USD MILLION)
  • TABLE 208. UNITED STATES INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PARASITIC INFECTIONS, 2025-2030 (USD MILLION)
  • TABLE 209. UNITED STATES INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VECTOR-BORNE INFECTIONS, 2018-2024 (USD MILLION)
  • TABLE 210. UNITED STATES INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VECTOR-BORNE INFECTIONS, 2025-2030 (USD MILLION)
  • TABLE 211. UNITED STATES INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 212. UNITED STATES INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
  • TABLE 213. UNITED STATES INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 214. UNITED STATES INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 215. UNITED STATES INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
  • TABLE 216. UNITED STATES INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
  • TABLE 217. CANADA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 218. CANADA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 219. CANADA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 220. CANADA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
  • TABLE 221. CANADA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REAGENTS & KITS, 2018-2024 (USD MILLION)
  • TABLE 222. CANADA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REAGENTS & KITS, 2025-2030 (USD MILLION)
  • TABLE 223. CANADA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 224. CANADA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
  • TABLE 225. CANADA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BLOOD, 2018-2024 (USD MILLION)
  • TABLE 226. CANADA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BLOOD, 2025-2030 (USD MILLION)
  • TABLE 227. CANADA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SWAB, 2018-2024 (USD MILLION)
  • TABLE 228. CANADA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SWAB, 2025-2030 (USD MILLION)
  • TABLE 229. CANADA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2024 (USD MILLION)
  • TABLE 230. CANADA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2025-2030 (USD MILLION)
  • TABLE 231. CANADA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 232. CANADA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PATHOGEN TYPE, 2025-2030 (USD MILLION)
  • TABLE 233. CANADA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL, 2018-2024 (USD MILLION)
  • TABLE 234. CANADA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL, 2025-2030 (USD MILLION)
  • TABLE 235. CANADA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 236. CANADA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 237. CANADA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BACTERIAL INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 238. CANADA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BACTERIAL INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
  • TABLE 239. CANADA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2024 (USD MILLION)
  • TABLE 240. CANADA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY FUNGAL INFECTIONS, 2025-2030 (USD MILLION)
  • TABLE 241. CANADA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2024 (USD MILLION)
  • TABLE 242. CANADA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PARASITIC INFECTIONS, 2025-2030 (USD MILLION)
  • TABLE 243. CANADA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VECTOR-BORNE INFECTIONS, 2018-2024 (USD MILLION)
  • TABLE 244. CANADA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VECTOR-BORNE INFECTIONS, 2025-2030 (USD MILLION)
  • TABLE 245. CANADA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 246. CANADA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
  • TABLE 247. CANADA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 248. CANADA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 249. MEXICO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 250. MEXICO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 251. MEXICO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 252. MEXICO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
  • TABLE 253. MEXICO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REAGENTS & KITS, 2018-2024 (USD MILLION)
  • TABLE 254. MEXICO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REAGENTS & KITS, 2025-2030 (USD MILLION)
  • TABLE 255. MEXICO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 256. MEXICO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
  • TABLE 257. MEXICO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BLOOD, 2018-2024 (USD MILLION)
  • TABLE 258. MEXICO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BLOOD, 2025-2030 (USD MILLION)
  • TABLE 259. MEXICO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SWAB, 2018-2024 (USD MILLION)
  • TABLE 260. MEXICO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SWAB, 2025-2030 (USD MILLION)
  • TABLE 261. MEXICO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2024 (USD MILLION)
  • TABLE 262. MEXICO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2025-2030 (USD MILLION)
  • TABLE 263. MEXICO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 264. MEXICO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PATHOGEN TYPE, 2025-2030 (USD MILLION)
  • TABLE 265. MEXICO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL, 2018-2024 (USD MILLION)
  • TABLE 266. MEXICO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL, 2025-2030 (USD MILLION)
  • TABLE 267. MEXICO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 268. MEXICO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 269. MEXICO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BACTERIAL INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 270. MEXICO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BACTERIAL INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
  • TABLE 271. MEXICO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2024 (USD MILLION)
  • TABLE 272. MEXICO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY FUNGAL INFECTIONS, 2025-2030 (USD MILLION)
  • TABLE 273. MEXICO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2024 (USD MILLION)
  • TABLE 274. MEXICO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PARASITIC INFECTIONS, 2025-2030 (USD MILLION)
  • TABLE 275. MEXICO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VECTOR-BORNE INFECTIONS, 2018-2024 (USD MILLION)
  • TABLE 276. MEXICO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VECTOR-BORNE INFECTIONS, 2025-2030 (USD MILLION)
  • TABLE 277. MEXICO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 278. MEXICO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
  • TABLE 279. MEXICO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 280. MEXICO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 281. BRAZIL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 282. BRAZIL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 283. BRAZIL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 284. BRAZIL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
  • TABLE 285. BRAZIL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REAGENTS & KITS, 2018-2024 (USD MILLION)
  • TABLE 286. BRAZIL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REAGENTS & KITS, 2025-2030 (USD MILLION)
  • TABLE 287. BRAZIL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 288. BRAZIL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
  • TABLE 289. BRAZIL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BLOOD, 2018-2024 (USD MILLION)
  • TABLE 290. BRAZIL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BLOOD, 2025-2030 (USD MILLION)
  • TABLE 291. BRAZIL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SWAB, 2018-2024 (USD MILLION)
  • TABLE 292. BRAZIL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SWAB, 2025-2030 (USD MILLION)
  • TABLE 293. BRAZIL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2024 (USD MILLION)
  • TABLE 294. BRAZIL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2025-2030 (USD MILLION)
  • TABLE 295. BRAZIL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 296. BRAZIL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PATHOGEN TYPE, 2025-2030 (USD MILLION)
  • TABLE 297. BRAZIL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL, 2018-2024 (USD MILLION)
  • TABLE 298. BRAZIL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL, 2025-2030 (USD MILLION)
  • TABLE 299. BRAZIL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 300. BRAZIL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 301. BRAZIL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BACTERIAL INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 302. BRAZIL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BACTERIAL INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
  • TABLE 303. BRAZIL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2024 (USD MILLION)
  • TABLE 304. BRAZIL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY FUNGAL INFECTIONS, 2025-2030 (USD MILLION)
  • TABLE 305. BRAZIL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2024 (USD MILLION)
  • TABLE 306. BRAZIL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PARASITIC INFECTIONS, 2025-2030 (USD MILLION)
  • TABLE 307. BRAZIL INFECTIOUS DIS